Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor…
Iterion Therapeutics, Inc. ("Iterion"), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced that it has raised $17 million USD in a…
Read More...
Read More...
